In an announcement today, Catalent Biologics and Valerius Biopharma revealed that they will be collaborating on the development and manufacturing of Valerius’ biosimilar products.
In an announcement released today, Catalent Biologics and Valerius Biopharma revealed that they will be collaborating on the development and manufacturing of Valerius’ biosimilar products.
Through the partnership, Catalent will be responsible for providing cell line development and manufacturing processes from phase 1 clinical trials through commercial marketing of the an eventual biosimilar product.
“We selected Catalent as our development and manufacturing partner because of their technical knowledge and expertise in the current good manufacturing practices…manufacture of biosimilars, and proven track record in bringing innovative treatments to market,” said Andreas Herrmann, CEO of Valerius.
Catalent utilizes proprietary technology to create production cell lines through the transduction of targeted cells. Reportedly, the company already has produced 7 biosimilars using its technology that are available on the global market.
“We are pleased to partner with Valerius on their biologic-based therapeutics for many important indications. We look forward to supporting them in their goal of producing affordable biosimilars that will provide equal access to medicinal products,” said vice president and general manager of drug substance and bioanalytical services of Catalent Biologics, Mike Reilly.
Financial terms of the agreement were not disclosed.
This collaboration is the latest in a wave of partnerships, mergers, and acquisitions to date. Last week, Amneal Pharmaceuticals announced it will be combining efforts with Spain-based mAbxience as the exclusive US partner for a potential bevacizumab (Avastin) biosimilar. This agreement marked the third biosimilar deal licensed by Amneal.
Earlier this year, fellow biosimilar developer Mylan, in its Investor Day presentation, highlighted its own partnerships with Biocon, Momenta, and Revance, and emphasized that its strategy includes acquiring biosimilar molecules.
Also this spring, Biogen indicated that it expects to increase its stake in a partnership with Samsung BioLogics in their joint venture, Samsung Bioepis.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.